MFAP4 is a novel prognostic biomarker in glioma correlating with immunotherapy resistance and ferroptosis
Our study demonstrated that MFAP4 is aberrantly overexpressed in gliomas and correlates with adverse clinicopathological features. MFAP4 has relevance in regulating both tumor immunity and iron death, and cellular function assays have demonstrated that MFAP4 promotes the proliferation, migration, and invasion of glioma cells.
Authors
- Wei Su (ORCID: https://orcid.org/0000-0003-1289-4403)
- Jiateng Zhong (ORCID: https://orcid.org/0000-0003-1570-1750)
- Yuanhao Lv
- Wenyu Di
- Min Zhang (ORCID: https://orcid.org/0000-0002-2001-7147)
- Tianfang Hou
- Yuankai Shi (ORCID: https://orcid.org/0000-0002-3342-4964)
- Ying Gao (ORCID: https://orcid.org/0000-0002-9156-9483)
- Jiaqi Tian
- Zhaoyi Li
- Yiyang Chen
- Minghui Xu (ORCID: https://orcid.org/0000-0003-3444-8332)
Institutions
- University of Shanghai for Science and Technology (CN)
- First Affiliated Hospital of Xinxiang Medical University (CN)
- Henan Medical University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-02-21
- DOI
- https://doi.org/10.3389/fphar.2025.1551863
- Citations
- 8
- Primary Topic
- Ferroptosis and cancer prognosis
- Type
- article
- Field-Weighted Citation Impact
- 12.15